1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Pipeline Review, H2 2020, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.
Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 11, 2, 2, 12, 6 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 1 molecules, respectively.
Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Epidermolysis Bullosa - Overview
- Epidermolysis Bullosa - Therapeutics Development
- Epidermolysis Bullosa - Therapeutics Assessment
- Epidermolysis Bullosa - Companies Involved in Therapeutics Development
- Epidermolysis Bullosa - Drug Profiles
- Epidermolysis Bullosa - Dormant Projects
- Epidermolysis Bullosa - Discontinued Products
- Epidermolysis Bullosa - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Epidermolysis Bullosa, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, H2 2020
- Epidermolysis Bullosa - Pipeline by Aegle Therapeutics Corp, H2 2020
- Epidermolysis Bullosa - Pipeline by Almirall SA, H2 2020
- Epidermolysis Bullosa - Pipeline by Amryt Pharma Plc, H2 2020
- Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, H2 2020
- Epidermolysis Bullosa - Pipeline by APR Applied Pharma Research SA, H2 2020
- Epidermolysis Bullosa - Pipeline by Avicanna Inc, H2 2020
- Epidermolysis Bullosa - Pipeline by Berg LLC, H2 2020
- Epidermolysis Bullosa - Pipeline by BioVec Pharma Inc, H2 2020
- Epidermolysis Bullosa - Pipeline by Castle Creek Biosciences Inc, H2 2020
- Epidermolysis Bullosa - Pipeline by Celularity Inc, H2 2020
- Epidermolysis Bullosa - Dormant Projects, H2 2020
- Epidermolysis Bullosa - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Epidermolysis Bullosa, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abeona Therapeutics Inc
- Aegle Therapeutics Corp
- Almirall SA
- Amryt Pharma Plc
- Anterogen Co Ltd
- APR Applied Pharma Research SA
- Avicanna Inc
- Berg LLC
- BioVec Pharma Inc
- Castle Creek Biosciences Inc
- Celularity Inc
- Constant Therapeutics LLC
- CSA Biotechnologies LLC
- Daewoong Pharmaceutical Co Ltd
- FIBRX Derm Inc
- Holostem Terapie Avanzate SRL
- Immusoft Corp
- InMed Pharmaceuticals Inc
- Kang Stem Biotech Co Ltd
- Krystal Biotech Inc
- LambdaGen Therapeutics
- Mesoblast Ltd
- OTR3 SAS
- Palvella Therapeutics LLC
- Panag Pharma Inc
- Phoenix Tissue Repair Inc
- Quoin Pharmaceuticals Ltd
- RegeneRx Biopharmaceuticals Inc
- RHEACELL GmbH & Co KG
- Shionogi & Co Ltd
- StemRIM Inc
- Therapicon Srl
- TWi Biotechnology Inc
- Vera Therapeutics Inc
- Wings Therapeutics
- Zikani Therapeutics Inc
